JOP20190244B1 - تركيبة علاجية لسرطان البروستاتا - Google Patents

تركيبة علاجية لسرطان البروستاتا

Info

Publication number
JOP20190244B1
JOP20190244B1 JOJO/P/2019/0244A JOP20190244A JOP20190244B1 JO P20190244 B1 JOP20190244 B1 JO P20190244B1 JO P20190244 A JOP20190244 A JO P20190244A JO P20190244 B1 JOP20190244 B1 JO P20190244B1
Authority
JO
Jordan
Prior art keywords
prostate cancer
effective amount
treatment formula
therapeutically effective
inhibitor
Prior art date
Application number
JOJO/P/2019/0244A
Other languages
Arabic (ar)
English (en)
Inventor
Linda Anne Snyder
Margaret K Yu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20190244(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of JOP20190244A1 publication Critical patent/JOP20190244A1/ar
Application granted granted Critical
Publication of JOP20190244B1 publication Critical patent/JOP20190244B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JOJO/P/2019/0244A 2017-04-13 2018-04-09 تركيبة علاجية لسرطان البروستاتا JOP20190244B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
PCT/US2018/026661 WO2018191141A1 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Publications (2)

Publication Number Publication Date
JOP20190244A1 JOP20190244A1 (ar) 2019-10-13
JOP20190244B1 true JOP20190244B1 (ar) 2024-04-18

Family

ID=62067858

Family Applications (2)

Application Number Title Priority Date Filing Date
JOJO/P/2019/0244A JOP20190244B1 (ar) 2017-04-13 2018-04-09 تركيبة علاجية لسرطان البروستاتا
JOJO/P/2023/0159A JOP20230159A1 (ar) 2017-04-13 2023-07-13 تركيبة علاجية لسرطان البروستاتا

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0159A JOP20230159A1 (ar) 2017-04-13 2023-07-13 تركيبة علاجية لسرطان البروستاتا

Country Status (33)

Country Link
US (4) US20180296574A1 (enExample)
EP (3) EP4176879A1 (enExample)
JP (3) JP7141408B2 (enExample)
KR (2) KR20190134718A (enExample)
CN (2) CN119235874A (enExample)
AU (2) AU2018251594A1 (enExample)
CA (1) CA3059562A1 (enExample)
CL (1) CL2019002871A1 (enExample)
CO (1) CO2019011591A2 (enExample)
CR (1) CR20190467A (enExample)
DK (1) DK3609497T3 (enExample)
DO (1) DOP2019000264A (enExample)
EA (1) EA201992430A1 (enExample)
ES (1) ES2931052T3 (enExample)
HR (1) HRP20221327T1 (enExample)
HU (1) HUE060460T2 (enExample)
IL (2) IL269879B2 (enExample)
JO (2) JOP20190244B1 (enExample)
LT (1) LT3609497T (enExample)
MA (1) MA48728B1 (enExample)
MD (1) MD3609497T2 (enExample)
MX (2) MX2019012296A (enExample)
MY (1) MY209010A (enExample)
NI (1) NI201900105A (enExample)
PE (1) PE20200444A1 (enExample)
PH (1) PH12019502317A1 (enExample)
PL (1) PL3609497T3 (enExample)
PT (1) PT3609497T (enExample)
RS (1) RS63832B1 (enExample)
SG (1) SG11201909552VA (enExample)
SM (1) SMT202200467T1 (enExample)
UA (1) UA129514C2 (enExample)
WO (1) WO2018191141A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119606965A (zh) 2016-07-29 2025-03-14 詹森药业有限公司 治疗前列腺癌的方法
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
AU2021269115A1 (en) * 2020-05-08 2023-01-19 Janssen Pharmaceutica Nv Treatment of prostate cancer with a combination of abiraterone acetate and niraparib
KR20230159510A (ko) * 2021-03-24 2023-11-21 화이자 인코포레이티드 Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
TWI828471B (zh) 2021-12-15 2024-01-01 大陸商湖南慧澤生物醫藥科技有限公司 醋酸阿比特龍的自微乳組合物和應用
CN118973555A (zh) * 2022-04-07 2024-11-15 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法
WO2025027138A1 (en) * 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
PL2061561T3 (pl) * 2006-08-25 2013-12-31 Janssen Oncology Inc Kompozycje do leczenia raka
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Also Published As

Publication number Publication date
CL2019002871A1 (es) 2019-12-27
ES2931052T3 (es) 2022-12-23
SG11201909552VA (en) 2019-11-28
MY209010A (en) 2025-06-16
US20240245710A1 (en) 2024-07-25
LT3609497T (lt) 2022-12-12
DOP2019000264A (es) 2020-07-15
EA201992430A1 (ru) 2020-02-28
KR20190134718A (ko) 2019-12-04
PE20200444A1 (es) 2020-02-28
EP4176879A1 (en) 2023-05-10
JP2022141881A (ja) 2022-09-29
MA48728B1 (fr) 2022-10-31
JP2024023344A (ja) 2024-02-21
EP3609497A1 (en) 2020-02-19
WO2018191141A1 (en) 2018-10-18
CA3059562A1 (en) 2018-10-18
BR112019021466A2 (pt) 2020-05-12
PT3609497T (pt) 2023-01-23
EP3609497B1 (en) 2022-10-12
US20180296574A1 (en) 2018-10-18
IL269879A (enExample) 2019-11-28
MX2019012296A (es) 2019-11-28
IL269879B2 (en) 2025-10-01
RS63832B1 (sr) 2023-01-31
MD3609497T2 (ro) 2023-03-31
HRP20221327T1 (hr) 2023-03-17
US20240398837A1 (en) 2024-12-05
JP2020516646A (ja) 2020-06-11
JP7141408B2 (ja) 2022-09-22
AU2024202346A1 (en) 2024-05-02
NI201900105A (es) 2020-03-11
MA48728A (fr) 2020-04-08
CN119235874A (zh) 2025-01-03
CN110753545A (zh) 2020-02-04
KR20260048358A (ko) 2026-04-09
JP7407880B2 (ja) 2024-01-04
SMT202200467T1 (it) 2023-01-13
MX2023009569A (es) 2023-08-22
JOP20230159A1 (ar) 2023-07-13
AU2018251594A1 (en) 2019-10-24
JOP20190244A1 (ar) 2019-10-13
AU2024202346B2 (en) 2026-01-22
CO2019011591A2 (es) 2020-02-28
US20220175801A1 (en) 2022-06-09
IL269879B1 (en) 2025-06-01
PL3609497T3 (pl) 2023-01-23
EP4176878A1 (en) 2023-05-10
UA129514C2 (uk) 2025-05-21
PH12019502317A1 (en) 2020-07-06
HUE060460T2 (hu) 2023-03-28
IL320452A (en) 2025-06-01
CR20190467A (es) 2020-03-09
DK3609497T3 (da) 2022-10-31

Similar Documents

Publication Publication Date Title
JOP20230159A1 (ar) تركيبة علاجية لسرطان البروستاتا
MX2020013348A (es) Anticuerpos biespecificos contra dll3-cd3.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12019501896A1 (en) Therapeutic dendrimers
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
MX2021010252A (es) Inhibidores del receptor de glucocorticoides.
EP3638269A4 (en) COMPOSITIONS AND PROCEDURES FOR IMPROVING RADIOTHERAPY AGAINST CANCER
EA201591967A1 (ru) Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2017011237A (es) Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.
PH12020550151A1 (en) Methods of treating prostate cancer
JOP20220292A1 (ar) صياغات صيدلانية من أسيتات أبيراتيرون ونيراباريب
LT3880186T (lt) Pd-1 inhibitorių skyrimas į pažeidimo vietą odos vėžiui gydyti
MX2024012369A (es) Terapia combinada para el tratamiento del cancer
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
MX2019011749A (es) Reduccion de la expresion de beta-catenina para potenciar la inmunoterapia.
EA201990859A1 (ru) Ингибиторы глюкокортикоидного рецептора